Please login to the form below
Lisocabtagene maraleucel
This page shows the latest Lisocabtagene maraleucel news and features for those working in and with pharma, biotech and healthcare.
BMS reports strong growth as its Q3 results beat predictions
up from $24m in Q2, while Breyanzi (lisocabtagene maraleucel), launched this year in lymphoma, had $30m in sales, up from $17m earlier in the year.
Latest news
-
Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study
The ongoing TRANSFORM study is evaluating Breyanzi (lisocabtagene maraleucel) compared to current standard of care regimens for LBCL, including high-dose chemotherapy (HDCT) and haematopoietic stem cell transplant (HSCT).
-
BMS’ CAR T therapy Breyanzi shows benefit in B-cell lymphoma study
The ongoing TRANSFORM study is evaluating Breyanzi (lisocabtagene maraleucel) compared to current standard of care regimens for LBCL, including high-dose chemotherapy (HDCT) and hematopoietic stem cell transplant (HSCT).
-
Yescarta gains first FDA approval for indolent follicular lymphoma
Also approved for the treatment of large B-cell lymphoma is Novartis’ rival CAR-T therapy Kymriah (tisagenlecleucel) and Bristol Myers Squibb’s (BMS) Breyanzi (lisocabtagene maraleucel), which are both approved
-
FDA approves BMS’ blood cancer CAR T therapy after delay
2020. The FDA has cleared Breyanzi (lisocabtagene maraleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy,
-
FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions
BMS picked up liso-cel 9 (lisocabtagene maraleucel) following its $74bn takeover of Celgene last year – the CAR-T therapy is one of the key assets critical to the potential payout
More from news
Approximately 1 fully matching, plus 17 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
Liso-cel (lisocabtagene maraleucel, JCAR-017) is an immunotherapy comprised of autologous T cells genetically modified (via lentiviral vector) to express an anti-CD19 chimeric antigen receptor (CAR).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Sanofi Global Health unveils new nonprofit Impact brand
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- First evidence-based guide launched to put patients at heart of digital innovations
- Roche shares new positive Ocrevus data for MS patients
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- A creative awakening – how pharma is bringing innovation to the patient journey
- Country report: The healthcare market in South Korea
- European Commission approves potential new treatment for Pompe disease
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
